TL1A

Home
Ligands
TL1A (Human)

GtoPdb Ligand ID: 5071

Synonyms: Tumor necrosis factor ligand superfamily member 15, membrane form

Compound class: Endogenous peptide in human, mouse or rat

Comment: TL1A occurs as both membrane‐bound and soluble forms. It principally functions as a negative modulator of epithelial cell proliferation. Inhibiting the TL1A/death receptor 3 (TNFRSF25) pathway has been proposed as mechanism to treat inflammatory bowel disease [1]. In addition, TL1A has been associated with tumourigenesis and progression of some gastrointestinal malignancies [3,5,7], making it a target of interest for the development of novel anti-cancer drugs.

Species: Human

No information available.

No information available.

Summary of Clinical Use
TL1A is being evaluated as a therapeutic target as a novel mechanism for ulcerative colitis treatment. PF-06480605 is a first-in-class TL1A blocking monoclonal antibody that inhibits pro-inflammatory cytokine production by T cell subsets [1].

Summary of Clinical Use

TL1A is being evaluated as a therapeutic target as a novel mechanism for ulcerative colitis treatment. PF-06480605 is a first-in-class TL1A blocking monoclonal antibody that inhibits pro-inflammatory cytokine production by T cell subsets [1].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT04090411	A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis	Phase 2 Interventional	Pfizer		1